Answers are grounded in this paper and cite their sources.
Juvenile myelomonocytic leukaemia (JMML) is a highly aggressive myeloid neoplasm of early childhood. Currently the only curative treatment for this potentially fatal disease is haematopoietic stem cell transplantation (HSCT), but cure rate is only 50%. As bridge-therapy prior to HSCT, cytoreductive chemotherapy is usually given. Some studies have shown effective and sustained response to chemotherapy with isotretinoin, a differentiating agent. Here, we describe a successfully managed case of JMML in Bangladesh.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: